Graft Injury and -transplantation in Liver Transplant Patients with COVID-19

Overview

Journal J Liver Transpl

Date 2024 Apr 15

PMID 38620664

Authors

Alexander Ng

Affiliations

Soon will be listed here.

Abstract

This article discusses the current scene of liver transplantation (LT) in light of the impact of COVID-19, with particular emphasis on the possibility of graft injury and re-transplantation in LT patients infected with SARS-CoV-2. A major concern is whether such patients experience a more severe form of disease which may lead to a higher risk of acute, irreversible liver injury. If this is serious, it may necessitate re-transplantation. This article aims to raise awareness in this relatively under-researched domain. More studies are required to evaluate this issue since it has strong implications in healthcare resource allocation and clinical decision-making. Several potential research directions are proposed, including the possibility of prolonging bridging therapy for non-urgent LT cases: patients with hepatocellular carcinoma; and whether hepatoprotective agents play a role in liver-sparing during SARS-CoV-2 infection. There is also substantial discussion of the relevance of lung injury in LT patients with COVID-19 since it is not uncommon regarding the high expression of ACE2 receptors in the lungs, and that lung injury remains the major cause of death in patients with chronic liver disease.

References

Jaffe A, Schilsky M, Deshpande R, Batra R . Liver Transplantation in the Time of COVID19: Barriers and Ethical Considerations for Management and Next Steps. Hepatol Commun. 2020; 4(9):1242-1256. PMC: 7361607. DOI: 10.1002/hep4.1568. View

Becchetti C, Zambelli M, Pasulo L, Donato M, Invernizzi F, Detry O . COVID-19 in an international European liver transplant recipient cohort. Gut. 2020; 69(10):1832-1840. PMC: 7335697. DOI: 10.1136/gutjnl-2020-321923. View

Solanich X, Antoli A, Padulles N, Fanlo-Maresma M, Iriarte A, Mitjavila F . Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: The TACROVID trial protocol. Contemp Clin Trials Commun. 2021; 21:100716. PMC: 7817439. DOI: 10.1016/j.conctc.2021.100716. View

Raja M, Mendoza M, Villavicencio A, Anjan S, Reynolds J, Kittipibul V . COVID-19 in solid organ transplant recipients: A systematic review and meta-analysis of current literature. Transplant Rev (Orlando). 2020; 35(1):100588. PMC: 7666542. DOI: 10.1016/j.trre.2020.100588. View

Dumortier J, Duvoux C, Roux O, Altieri M, Barraud H, Besch C . Covid-19 in liver transplant recipients: the French SOT COVID registry. Clin Res Hepatol Gastroenterol. 2021; 45(4):101639. PMC: 7843027. DOI: 10.1016/j.clinre.2021.101639. View

Merola J, Schilsky M, Mulligan D . The Impact of COVID-19 on Organ Donation, Procurement, and Liver Transplantation in the United States. Hepatol Commun. 2020; 5(1):5-11. PMC: 7537114. DOI: 10.1002/hep4.1620. View

Rabiee A, Sadowski B, Adeniji N, Perumalswami P, Nguyen V, Moghe A . Liver Injury in Liver Transplant Recipients With Coronavirus Disease 2019 (COVID-19): U.S. Multicenter Experience. Hepatology. 2020; 72(6):1900-1911. PMC: 7537191. DOI: 10.1002/hep.31574. View

Kim D, Yoon S, Ji S, Yang J, Kim Y, Lee S . Ursodeoxycholic acid improves liver function via phenylalanine/tyrosine pathway and microbiome remodelling in patients with liver dysfunction. Sci Rep. 2018; 8(1):11874. PMC: 6082879. DOI: 10.1038/s41598-018-30349-1. View

Li M, Li L, Zhang Y, Wang X . Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty. 2020; 9(1):45. PMC: 7186534. DOI: 10.1186/s40249-020-00662-x. View

10.

Colmenero J, Rodriguez-Peralvarez M, Salcedo M, Arias-Milla A, Munoz-Serrano A, Graus J . Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. J Hepatol. 2020; 74(1):148-155. PMC: 7395653. DOI: 10.1016/j.jhep.2020.07.040. View

11.

Marjot T, Moon A, Cook J, Abd-Elsalam S, Aloman C, Armstrong M . Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. J Hepatol. 2020; 74(3):567-577. PMC: 7536538. DOI: 10.1016/j.jhep.2020.09.024. View

12.

Bangash M, Patel J, Parekh D . COVID-19 and the liver: little cause for concern. Lancet Gastroenterol Hepatol. 2020; 5(6):529-530. PMC: 7270582. DOI: 10.1016/S2468-1253(20)30084-4. View

13.

Ng A . Clinical Efficacy of Tofacitinib in Moderate to Severe Ulcerative Colitis. J Crohns Colitis. 2021; 15(10):1774. DOI: 10.1093/ecco-jcc/jjab062. View

14.

Thies J, Teklote J, Clauer U, Tox U, Klar E, Hofmann W . The efficacy of N-acetylcysteine as a hepatoprotective agent in liver transplantation. Transpl Int. 1998; 11 Suppl 1:S390-2. DOI: 10.1007/s001470050505. View

15.

Webb G, Marjot T, Cook J, Aloman C, Armstrong M, Brenner E . Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. Lancet Gastroenterol Hepatol. 2020; 5(11):1008-1016. PMC: 7455160. DOI: 10.1016/S2468-1253(20)30271-5. View

16.

Hilmi I, Peng Z, Planinsic R, Damian D, Dai F, Tyurina Y . N-acetylcysteine does not prevent hepatorenal ischaemia-reperfusion injury in patients undergoing orthotopic liver transplantation. Nephrol Dial Transplant. 2010; 25(7):2328-33. DOI: 10.1093/ndt/gfq077. View

17.

Chen F, Chen W, Chen J, Xu D, Xie W, Wang X . Clinical features and risk factors of COVID-19-associated liver injury and function: A retrospective analysis of 830 cases. Ann Hepatol. 2020; 21:100267. PMC: 7548062. DOI: 10.1016/j.aohep.2020.09.011. View

18.

Ng A . Liver Injury in Liver Transplant Patients With COVID-19: A Histopathologic Analysis. Clin Gastroenterol Hepatol. 2021; 19(7):1508-1509. PMC: 7873596. DOI: 10.1016/j.cgh.2021.02.016. View

19.

Manini M, Sangiovanni A, Martinetti L, Vigano D, La Mura V, Aghemo A . Transarterial chemoembolization with drug-eluting beads is effective for the maintenance of the Milan-in status in patients with a small hepatocellular carcinoma. Liver Transpl. 2015; 21(10):1259-69. DOI: 10.1002/lt.24196. View

20.

Belsky J, Tullius B, Lamb M, Sayegh R, Stanek J, Auletta J . COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients. J Infect. 2021; 82(3):329-338. PMC: 7859698. DOI: 10.1016/j.jinf.2021.01.022. View